Exact Sciences
360Dx Top 30 Drops 6 Percent in May
Of the 30 companies in the index, 21 saw their share prices decrease, while nine saw their stock prices rise.
Exact Sciences Reports 24 Percent Spike in Q1 Revenues, Ups Full-Year Revenue Guidance
Exact reported revenues of $602.5 million compared to $486.6 million a year ago, surpassing analysts' average estimate of $543.5 million.
Vigil Neuroscience Launches No-Cost Genetic Counseling, Testing Program for Rare Neurologic Disorder
The firm is partnering with InformedDNA and PreventionGenetics to improve diagnosis of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.
UBS Initiates Coverage of Exact Sciences, Natera, Guardant Health
The investment bank gave Natera and Guardant Health a Buy rating and Exact Sciences a Neutral rating.
VieCure, Exact Sciences Partner to Ease Genomic Testing Access, Interpretation
The AI-based decision support firm will integrate Exact's tests into its clinical care management tool, aimed at community oncologists.
Feb 1, 2023
360Dx Top 30 Starts the Year up 1 Percent
Nov 3, 2022
Exact Sciences Q3 Revenues Rise 15 Percent
Aug 3, 2022
Jul 1, 2022
360Dx Top 30 Drops 5 Percent in June
Jun 14, 2022